Abstract: Point of care diagnostics is one of the fast-growing categories within the in vitro diagnostics market, and their development continues to expand rapidly. The expansion of point of care diagnostics has recently seen a significant uptick since the COVID-19 pandemic. The response to COVID-19 accelerated the development of point of care diagnostics, unlocked new opportunities for rapid growth, and brought many new technologies to the market. In their current form, point of care diagnostic devices can provide rapid and accurate results faster than their laboratory counterparts for a fraction of the cost. In this presentation, I’ll begin with discussing the history of point of care diagnostics. I’ll then present a landscape of the current menu of point of care diagnostics. I’ll showcase emerging and innovative technologies from top academic institutions. Finally, I’ll end the presentation by discussing the potential disruptions to laboratory-based in vitro diagnostics.
The first portion of the presentation will present a history and overview of point of care diagnostics. I will discuss different categories of tests, including immunochromatographic assays, enzyme-based immunoassays and nucleic acid amplification tests. The discussion will center around the successful deployment of these diagnostics and their relative strengths.
Point of care diagnostics have significantly improved since their inception and continue to show improvements in speed, accuracy, and multiplexing capabilities. Emerging technological innovations are driving the improvement of these devices. I will highlight emerging technologies such as lab-on-a-chip, artificial intelligence applications, multiplexed assays and wearable devices.
Finally, we will analyze market trends and forecast the impact of these diagnostics on the disruption of laboratory-based in vitro diagnostics. The point of care diagnostics market has rapidly grown over the past two decades. Record numbers of diagnostic manufacturers are pursuing regulatory approval for CLIA status and CE Mark for self-use. In addition, point of care diagnostics are approaching the ability to produce laboratory-quality results in a fraction of the time for a fraction of the cost.
